Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History BBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics BBIO

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

BridgeBio Pharma Inc

BBIO
Current price
46.74 USD -0.28 USD (-0.60%)
Last closed 46.97 USD
ISIN US10806X1028
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 8 943 394 816 USD
Yield for 12 month +80.25 %
1Y
3Y
5Y
10Y
15Y
BBIO
21.11.2021 - 28.11.2021

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California. Address: 3160 Porter Drive, Palo Alto, CA, United States, 94304

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

59.63 USD

P/E Ratio

Dividend Yield

Financials BBIO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures BBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+221 902 000 USD

Last Year

+9 303 000 USD

Current Quarter

+116 633 000 USD

Last Quarter

+5 882 000 USD

Current Year

+218 024 000 USD

Last Year

+6 857 000 USD

Current Quarter

+116 028 000 USD

Last Quarter

+3 798 000 USD
EBITDA -662 649 984 USD
Operating Margin TTM -89.00 %
Price to Earnings
Return On Assets TTM -48.27 %
PEG Ratio
Return On Equity TTM -1 789.67 %
Wall Street Target Price 59.63 USD
Revenue TTM 127 415 000 USD
Book Value -8.68 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -44.80 %
Dividend Yield
Gross Profit TTM 121 496 000 USD
Earnings per share -3.56 USD
Diluted Eps TTM -3.56 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation BBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 80.53
Price Sales TTM 70.19
Enterprise Value EBITDA -9.40
Price Book MRQ 123.68

Technical Indicators BBIO

For 52 Weeks

21.72 USD 48.68 USD
50 Day MA 39.18 USD
Shares Short Prior Month 21 119 414
200 Day MA 32.52 USD
Short Ratio 8.11
Shares Short 21 834 552
Short Percent 18.75 %